Immunological Pathways and Efficacy of COVID-19 Vaccines: Learned Lessons from Research and Development to Clinical Trials | Chapter 6 | Medical Science: Trends and Innovations Vol. 1

Background: The global outbreak of SARS-CoV-2 prompted an unprecedented race to develop effective vaccines. Previous pandemics provided insight into vaccine design, but COVID-19 demanded novel strategies to combat high transmission rates and mutational variability. The primary focus was to elicit strong humoral and cell-mediated immune responses targeting the viral spike protein, which mediates host cell entry.

Objective: This book chapter aims to evaluate the immunological mechanisms underlying the effectiveness of COVID-19 vaccines, analyze their ability to generate adaptive and innate immune responses, and identify potential strategies to enhance vaccine efficacy amid ongoing viral mutations.

Methods: A comprehensive analysis was conducted on preclinical and clinical studies evaluating mRNA-based, adenovirus-vectored, and inactivated virus vaccines. Emphasis was placed on antibody generation, T-cell activation, cytokine production, and long-term immune memory. Additionally, data on booster strategies and mixed vaccine regimens were reviewed to assess their potential to counteract emerging variants.

Results: Findings demonstrate that mRNA vaccines elicit robust antibody production and Th1-biased cellular responses shortly after administration, while adenovirus-vectored vaccines generate polyclonal antibodies capable of broad immune activation. Both approaches significantly reduce hospitalization and severe illness. However, immune durability appears variable, necessitating booster doses to sustain immunity. Studies also highlight reduced efficacy against variants such as Delta and Omicron, underscoring the need for polyvalent formulations targeting multiple epitopes. Emerging evidence indicates that hybrid approaches, such as heterologous prime-boost regimens, enhance immunogenicity and mitigate antivector immunity.

Conclusions: COVID-19 vaccines have proven effective in reducing severe disease and hospitalization rates, yet challenges persist due to emerging variants and waning immunity. Strategies to enhance vaccine efficacy include targeting conserved viral epitopes, integrating novel adjuvants, and developing hybrid or polyvalent formulations. Global efforts should focus on equitable vaccine distribution, long-term monitoring, and adaptive booster strategies to ensure sustained protection. Future research must prioritize understanding innate immune contributions and optimizing dosing regimens to counteract evolving variants.

 

Author (s) Details

 

Sami El Khatib
Department of Biomedical Sciences, Lebanese International University, Khiyara-West Bekaa, 1108, Lebanon.

 

Please see the book here:- https://doi.org/10.9734/bpi/msti/v1/4015

 

COVID-19 Vaccine-induced Parsonage-turner Syndrome: A Case Study | Chapter 7 | Disease and Health Research - New Insights Vol. 1

 

The risk of neurological adverse effects is present in all contemporary vaccines. Parsonage-Turner syndrome (PTS), an uncommon peripheral nerve condition associated with coronavirus disease 2019 (COVID-19) immunization, has been reported in only a few cases. A concise literature review and the case of a 78-year-old male with no recent trauma or infection presented with chest pain and bilateral hand weakness following COVID-19 vaccination. 21 days following the initial dose, the patient received a second dose of the BNT162b2 COVID-19 vaccine three weeks before the onset of symptoms. The physical examination revealed significant weakness in the right-hand grasp and wrist flexion. The diagnostic workup revealed no underlying diabetes mellitus, infections, or other autoimmune diseases. The bilateral first dorsal interosseous and right deltoid, biceps, and triceps muscles exhibited decreased motor unit recruitment in nerve conduction investigations, including needle electromyography, confirming PTS. Occupational therapy and oral prednisone were administered to preserve the patient's range of motion. The pathophysiology and etiology of PTS are not entirely comprehended. Various factors, including genetic, environmental, and immunological predisposition, may contribute to the development of the syndrome. Infections, vaccines, and injuries are the most common causes of non-hereditary forms. No test can definitively corroborate or disprove the existence of PTS. Imaging modalities and electrodiagnostic studies are instrumental in eliminating alternative differential diagnoses.

 

 

Author(s)Details

Mohammad Asim Amjad
Pulmonary and Critical Care Medicine, The University of Texas Science Center at Houston, Houston, Texas, USA.

 

Zamara Hamid
Internal Medicine, Shifa International Hospital, Islamabad, Pakistan.

 

Yamini Patel
Internal Medicine, The Wright Center for Graduate Medical Educations, Scranton, PA, USA.

 

Mujtaba Husain
Internal Medicine, The Wright Center for Graduate Medical Educations, Scranton, PA, USA.

 

Ammad Saddique
Internal Medicine, The Wright Center for Graduate Medical Educations, Scranton, PA, USA

 

Adnan Liaqat
Pulmonary and Critical Care Medicine, Mclaren Health/Michigan State University, Lansing, MI, USA.

 

Pius Ochieng
Pulmonary and Critical Care Medicine, Geisinger Community Medical Center, Scranton, PA, USA.

 

Please see the book here- https://doi.org/10.9734/bpi/dhrni/v1/1189